PROTHENA CORP PUBLIC LTD CO (PRTA): restructuring charge — Prothena cuts 63% of workforce, expects $16-20M severance costs; two C-suite execs to leave Aug 1
PROTHENA CORP PUBLIC LTD CO
Workforce reduction of ~63% to cut operating costs; substantially complete by Q4 2025.
Expected severance and benefits $16-20M plus non-cash stock option acceleration.
Chief Regulatory Officer Carol D. Karp and Chief People Officer David A. Ford to depart Aug 1, 2025.
Follows May 23 decision to discontinue birtamimab development.
On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.
On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Carol D. Karp was terminated as Chief Regulatory Officer at PROTHENA CORP PUBLIC LTD CO.
Action
terminated
Role
Chief Regulatory Officer
Exact text from the filing
On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.
David A. Ford was terminated as Chief People Officer at PROTHENA CORP PUBLIC LTD CO.
Action
terminated
Role
Chief People Officer
Exact text from the filing
On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.
PROTHENA CORP PUBLIC LTD CO announced a restructuring with charges of approximately $16 to $20 million (approximate 63% reduction in its workforce).
Type
restructuring
Charge
approximately $16 to $20 million
Headcount
approximate 63% reduction in its workforce
Exact text from the filing
periods will be extended, pursuant to the terms of the option award agreements under which those stock options were granted. The Company expects to recognize approximately $16 to $20 million in total for severance and related benefits for employees laid off under the reduction in workforce and non-cash share-based compensation expense related to the
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.